Clinical Outcomes and Cost‐effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1524-4741|21|6|658-664

ISSN： 1075-122x

Source： THE BREAST JOURNAL, Vol.21, Iss.6, 2015-11, pp. : 658-664

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of Actual Hospital Costs versus DRG Revenues for In-Patient Treatment of Febrile Neutropenia during Adjuvant Anthracycline plus/minus Taxane-Based Chemotherapy for Primary Breast Cancer

By  

Oncology Research and Treatment, Vol. 34, Iss. 11, 2011-10 ,pp. : 614-618

Karger

Access to resources Recommend Favorite

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 3, 2018-03 ,pp. : 490-500

John Wiley & Sons Inc

Access to resources Recommend Favorite

G-CSF in the Prevention of Febrile Neutropenia in Chemotherapy in Breast Cancer Patients

By  

Oncology Research and Treatment, Vol. 29, Iss. 4, 2006-03 ,pp. : 171-178

Karger

Access to resources Recommend Favorite

Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

By  

Oncology Research and Treatment, Vol. 34, Iss. 5, 2011-04 ,pp. : 241-246

Karger

Access to resources Recommend Favorite

MONITOR‐GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy‐induced/febrile neutropenia prophylaxis

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 3, 2018-03 ,pp. : 241-246

John Wiley & Sons Inc

Access to resources Recommend Favorite